TOKYO - ASKA Pharmaceutical Co., Ltd. (Head Office: Minato-ku, Tokyo, President: Takashi Yamaguchi, hereinafter 'ASKA') is pleased to announce that it has completed the acquisition 24.9% shares of the Vietnamese pharmaceutical company, Ha Tay Pharmaceutical Joint Stock Company, and Hataphar became an affiliate company of ASKA under accounting rules for the equity method.

Overview of Share Acquisition

Number of Shares 6,575,421 (24.9%)

Acquisition Cost Not disclosed, based on confidentiality obligations in the share transfer agreement.

Overview of Hataphar

Company Name Ha Tay Pharmaceutical Joint Stock Company

Businesses Manufacturing, sales and importation of pharmaceuticals, nonprescription and nutraceutical products

Capital 211,274 million VND (1.01billion yen

Establishment 1965

Headquarters Hanoi, Vietnam

Net Sales (FY2019) 2,042,749,649,511 VND (9.80 billion yen)

Net Income (FY2019) 90,022,812,337 VND (0.43 billion yen)

Equity (FY2019) 312,146,627,850 VND (1.50 billion yen)

Total Assets (FY2019) 738,220,433,620 VND (3.54 billion yen)

Schedule

Share Acquisition Date January 15th, 2021

Future Financial Outlook

The impact of this Share Acquisition on the consolidated results of ASKA for FY2020 will be minor.

Contact:

Tel: +81 466-77-8336

Fax: +81 466-26-5879

(C) 2021 Electronic News Publishing, source ENP Newswire